Literature DB >> 12185581

Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines.

Izumi Miyake1, Yuko Hakomori, Azusa Shinohara, Toshie Gamou, Masaki Saito, Akihiro Iwamatsu, Ryuichi Sakai.   

Abstract

Shc family of docking proteins, ShcA, ShcB and ShcC, play roles in cellular signal transduction by binding to phosphotyrosine residues of various activated receptor tyrosine kinases. Both ShcB and ShcC proteins are selectively expressed in the neural system of adult mouse tissues. In most of neuroblastoma cells, obvious tyrosine phosphorylation of ShcC was observed, whereas expression of ShcB was considerably low. Phosphoproteins associated with hyperphosphorylated ShcC were purified from neuroblastoma cell lines, and identified by mass-spectrometry. Anaplastic lymphoma kinase (ALK), which turned out to be one of these phosphoproteins, was constitutively activated and associated with the PTB domain of ShcC in three neuroblastoma cells. In vitro kinase assay revealed that ShcC is a potent substrate of the activated ALK kinase. The ALK gene locus was significantly amplified in both of these cell lines, suggesting that gene amplification leads to constitutive activation of the ALK kinase, which results in hyperphosphorylation of ShcC. Constitutive activation of ALK appeared to interfere with signals from other receptor tyrosine kinases. ALK-ShcC signal activation, possibly caused by co-amplification with the N-myc gene, might give additional effects on malignant tumor progression of neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12185581     DOI: 10.1038/sj.onc.1205735

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  39 in total

1.  Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.

Authors:  E L Carpenter; E A Haglund; E M Mace; D Deng; D Martinez; A C Wood; A K Chow; D A Weiser; L T Belcastro; C Winter; S C Bresler; M Vigny; P Mazot; S Asgharzadeh; R C Seeger; H Zhao; R Guo; J G Christensen; J S Orange; B R Pawel; M A Lemmon; Y P Mossé
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

Review 2.  Emerging importance of ALK in neuroblastoma.

Authors:  Anna M Azarova; Gargi Gautam; Rani E George
Journal:  Semin Cancer Biol       Date:  2011-09-16       Impact factor: 15.707

3.  Cell density modulates SHC3 expression and survival of human glioblastoma cells through Fak activation.

Authors:  Alberto Azzalin; Elena Moretti; Eloisa Arbustini; Lorenzo Magrassi
Journal:  J Neurooncol       Date:  2014-07-26       Impact factor: 4.130

4.  ALK gene copy number gain and its clinical significance in hepatocellular carcinoma.

Authors:  Shou-Wei Jia; Sha Fu; Fang Wang; Qiong Shao; Hong-Bing Huang; Jian-Yong Shao
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

Review 5.  New insights into the genetics of neuroblastoma.

Authors:  Srishma Sridhar; Batool Al-Moallem; Hawra Kamal; Marta Terrile; Raymond L Stallings
Journal:  Mol Diagn Ther       Date:  2013-04       Impact factor: 4.074

Review 6.  Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.

Authors:  Thomas R Webb; Jake Slavish; Rani E George; A Thomas Look; Liquan Xue; Qin Jiang; Xiaoli Cui; Walter B Rentrop; Stephan W Morris
Journal:  Expert Rev Anticancer Ther       Date:  2009-03       Impact factor: 4.512

7.  Genes proximal and distal to MYCN are highly expressed in human neuroblastoma as visualized by comparative expressed sequence hybridization.

Authors:  Cornelia Stock; Eva Bozsaky; Franz Watzinger; Ulrike Poetschger; Lukas Orel; Thomas Lion; Agata Kowalska; Peter F Ambros
Journal:  Am J Pathol       Date:  2007-12-28       Impact factor: 4.307

Review 8.  Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.

Authors:  Andres Morales La Madrid; Andres Morales La Madrid; Nicholas Campbell; Sonali Smith; Susan L Cohn; Ravi Salgia
Journal:  Target Oncol       Date:  2012-09-12       Impact factor: 4.493

9.  The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL.

Authors:  Francesco E Boccalatte; Claudia Voena; Chiara Riganti; Amalia Bosia; Lucia D'Amico; Ludovica Riera; Mangeng Cheng; Bruce Ruggeri; Ole N Jensen; Valerie L Goss; Kimberly Lee; Julie Nardone; John Rush; Roberto D Polakiewicz; Michael J Comb; Roberto Chiarle; Giorgio Inghirami
Journal:  Blood       Date:  2008-10-09       Impact factor: 22.113

Review 10.  Anaplastic lymphoma kinase: signalling in development and disease.

Authors:  Ruth H Palmer; Emma Vernersson; Caroline Grabbe; Bengt Hallberg
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.